MPR Weekly Dose Podcast 69

An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.